LakePharma Announces its GMP Biorepository Facility near Boston is Now Operational, Plans Additional HiringAdded On: 2019-01-15
LakePharma announces its cGMP microBiomanufacturing Center is now operationalAdded On: 2018-12-18
LakePharma Expands Antibody Center Into New 40,000 sq. ft. San Carlos BuildingAdded On: 2018-08-14
Added On: 2018-06-05
Agreement Provides for Easy Access to H2L2 Platform Use with LakePharma's Discovery and Development Services
BELMONT, Calif. and CAMBRIDGE, Mass. and ROTTERDAM, Netherlands, June 5, 2018 /PRNewswire/ -- LakePharma and Harbour Antibodies BV, a Harbour BioMed subsidiary, today announced a technology partnership providing LakePharma the right to utilize Harbour Antibodies' patented, H2L2 transgenic mouse platform in its therapeutic antibody discovery service offerings to clients in pharmaceutical and therapeutic biotechnology companies.
Harbour Antibodies' patented H2L2 transgenic mice produce classical antibodies (two heavy and two light chain immunoglobulins) with fully human variable regions. In response to antigen challenge, the engineered mice produce in vivo affinity-matured, target-specific human antibodies with low risk for immunogenicity. The H2L2 platform has been used by more than thirty companies and organizations for antibody discovery. To date, two antibodies generated by the platform have entered clinical trials.
Hua Tu, Ph. D., Founder and Chief Executive Officer of LakePharma, commented: "Our clients are increasingly looking for accessible transgenic mouse platforms to discover unique therapeutic antibody candidates. We are excited to bundle the H2L2 technology, which has established a strong track record of success, into our high-quality antibody discovery service. This partnership provides pharma and biotech companies with unprecedented capacity and flexibility to discover fully human therapeutic antibodies via LakePharma's hybridoma-driven antibody discovery engine."
"Harbour Antibodies is delighted to team up with LakePharma in offering the H2L2 platform in a unique business model," said Dr. Jingsong Wang, CEO of Harbour BioMed. "Our approach is structured to facilitate easy access to the H2L2 platform through a pre-negotiated technology evaluation license and to readily integrate with LakePharma's services."
LakePharma is the leading US-based biologics company specializing in antibody engineering, antibody discovery, molecular engineering, protein chemistry, bioexpression, biofunction, bioprocessing, bioanalytics and µBIOMANUFACTURINGSM biologics manufacturing services for Phase 1 clinical trials. LakePharma focuses on integrated platforms to support projects throughout the drug discovery process. LakePharma offers dedicated client services and sophisticated software to provide real-time access to project data via a secure cloud-based portal. For more information, please visit www.lakepharma.com.